Alone in the spotlight, Pfizer CEO Bourla swears pure intentions in the rush to develop a Covid-19 vaccine. But will the public believe it?

Now that Moderna has shifted expectations on pivotal data for its Covid-19 vaccine to some time just after the election and AstraZeneca has been stalled …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Alone in the spotlight, Pfizer CEO Bourla swears pure intentions in the rush to develop a Covid-19 vaccine. But will the public believe it?

This article is available only to Premium subscribers

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

GSK defiant against vaccine challenges, will prioritize other growth areas

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Novo Nordisk sees growth slowing this year, plans CagriSema filing for 2026

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

Drugmakers seize on biomarkers to test the FDA's rare disease shift

Alone in the spot­light, Pfiz­er CEO Bourla swears pure in­ten­tions in the rush to de­vel­op a Covid-19 vac­cine. But will the pub­lic be­lieve it?

This article is available only to Premium subscribers

more like this

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

No­vo Nordisk sees growth slow­ing this year, plans Ca­griSe­ma fil­ing for 2026

New study will try to stop Alzheimer’s decades be­fore it be­gins, us­ing ex­per­i­men­tal Eli Lil­ly drug

Drug­mak­ers seize on bio­mark­ers to test the FDA's rare dis­ease shift

Alone in the spotlight, Pfizer CEO Bourla swears pure intentions in the rush to develop a Covid-19 vaccine. But will the public believe it?

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

GSK defiant against vaccine challenges, will prioritize other growth areas

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Novo Nordisk sees growth slowing this year, plans CagriSema filing for 2026

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

Drugmakers seize on biomarkers to test the FDA's rare disease shift